Last reviewed · How we verify

Streptococcal infectious disease — Treatment Landscape & Competitive Intelligence

Streptococcal infectious disease (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Streptococcal infectious disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lincocin LINCOMYCIN Pfizer lincomycin 1964-01-01
Bicillin C-R benzathine benzylpenicillin Pfizer benzathine benzylpenicillin 1952-01-01
Penicillin G Potassium In Plastic Container Benzylpenicillin Pfizer Penicillin-class Antibacterial 1947-01-01
penicillin penicillin Karlstad University Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 3 drugs in Streptococcal infectious disease
  2. · 1 drug in Streptococcal infectious disease
  3. Karlstad University · 1 drug in Streptococcal infectious disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Streptococcal infectious disease:

Cite this brief

Drug Landscape (2026). Streptococcal infectious disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/streptococcal-infectious-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing